ClinicalTrials.gg
Not yet recruitingNCT07940478Updated Nov 16, 2026

A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

A Phase 2 interventional study of QL1706 (Iparomlimab/Tuvonralimab) in Hepatecellular Carcinoma, sponsored by Fujian Cancer Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Fujian Cancer Hospital · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular — 14 open to participants now, 14 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Carcinoma, Hepatocellular.

Planned enrollment
6th of 14
43 · median 36
Started
2027
the only one that year
Phase 2
8 of 14
8 open now
Primary completion
2030-03
later than 13 of 13 live
Registered
14th of 14
by date
Lead sponsor
1 of 14
Fujian Cancer Hospital

Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, this one is the 6th largest by planned enrollment, is the only one that started in 2027, is one of 8 in phase 2, reaches primary completion later than 13 of the 13 other live ones, and was the 14th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

14 of the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

About Iparomlimab/Tuvonralimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a single-arm, phase II clinical study. A total of 43 treatment-naive hepatocellular carcinoma patients with portal vein tumor thrombus (PVTT) are planned to be enrolled. Eligible subjects will enter the study after signing informed consent.

Each subject will receive TAE-HAIC combined with Iparomlimab and Tuvonralimab (QL1706, 7.5 mg/kg, iv, Q3W) and lenvatinib (8 mg for body weight \<60 kg, or 12 mg for body weight >60 kg, po, QD). QL1706 is administered on Day 2 of interventional therapy, with a 21-day cycle. Lenvatinib is taken orally on the day of discharge after QL1706 infusion. The HAIC cycles will be determined by investigators according to the subject's condition, ranging from 3 to 6 cycles.

QL1706 and lenvatinib can be maintained for up to 2 years, until disease progression (PD, comprehensively assessed by investigators based on imaging and clinical status), loss of clinical benefit, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or other treatment discontinuation criteria specified in the protocol, whichever occurs first. For subjects withdrawn due to PD, subsequent treatment options may include targeted agents (apatinib, regorafenib, ramucirumab), immunotherapy (pembrolizumab, camrelizumab, tislelizumab), traditional Chinese medicine preparations with indications for hepatocellular carcinoma, best supportive care or palliative care, in accordance with the 2025 CSCO or NCCN guidelines, at the investigator's discretion.

Contrast-enhanced CT or MRI (PET-CT when necessary) will be performed every 6 weeks (±7 days) from treatment initiation for efficacy assessment until PD, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy or other protocol-specified discontinuation reasons, whichever comes first. Subjects will continue safety visits and survival follow-up after treatment discontinuation. Safety follow-up lasts for 30 days after the last dose (90 days for immune-related adverse events). Survival follow-up is conducted every 3 months within 2 years and every 6 months thereafter up to 3 years after treatment discontinuation or death. For subjects stopping treatment for reasons other than PD or death, tumor progression follow-up including serum tumor markers (AFP, PIVKA-II (DCP)) and imaging examinations (dynamic contrast-enhanced MRI/CT of abdomen and pelvis) will be arranged.

TAE: particulate embolic agents such as gelatin sponge particles, blank microspheres and PVA particles are used to embolize tumor feeding arteries.

HAIC-FOLFOX regimen: oxaliplatin 85 mg/m² intra-arterial infusion over 2-3 h, leucovorin 400 mg/m² intra-arterial infusion over 1-2 h, fluorouracil 400 mg/m² intra-arterial bolus followed by continuous intra-arterial infusion of 2400 mg/m² for 23 h or 46 h, repeated every 3 weeks.

03

Conditions studied

  • Hepatecellular Carcinoma

Keywords

  • immunotherapy
  • hepatocellular carcinoma
  • TAE
  • HAIC
  • PVTT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years inclusive.
  • (ECOG) performance status score of 0-1, and score ≤ 7.
  • Diagnosed by imaging or histopathology with BCLC stage C hepatocellular carcinoma complicated with portal-vein tumor thrombus (Vp1-4); extrahepatic are permitted. The primary lesion is deemed unresectable by multidisciplinary team (MDT) assessment.
  • At least one according to 1.1 (longest diameter ≥ 10 mm for measurable lesion on spiral CT, or short-axis diameter ≥ 15 mm for malignant lymph node).
  • No prior systemic or locoregional therapies for hepatocellular carcinoma, including but not limited to chemotherapy, targeted therapy, immunotherapy, radiotherapy, surgery, hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), etc.
  • Expected survival ≥ 3 months.
  • Laboratory values obtained within 7 days prior to first study drug administration meet the following criteria (no blood products, hematopoietic growth factors, albumin, or other corrective therapies judged by the investigator permitted within 14 days before laboratory testing):

    1. Biochemistry: (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤ 5 × (ULN); total serum (TBIL) ≤ 2 × ULN; serum creatinine ≤ 1.5 × ULN, or > 50 mL/min (calculated by the Cockcroft-Gault formula); serum albumin ≥ 30 g/L.
    2. Hematology: (Hb) ≥ 9.0 g/dL; no red-blood-cell transfusion within 1 week (including the day of baseline Hb testing); (ANC) ≥ 1.5 × 10⁹/L; count ≥ 75 × 10⁹/L; no platelet transfusion within 1 week (including the day of baseline platelet testing).
    3. Coagulation: (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (i.e., no bleeding episode in the preceding 14 days), the investigator shall confirm that INR falls within a safe and effective therapeutic range.
    4. Urinalysis: urine protein \< 2+ by dipstick or routine urinalysis; if urine protein ≥ 2+, 24-hour urinary protein quantification must be \< 1 g/24 h.
  • No to chemotherapy, targeted agents or immunotherapy.
  • Women of must have a negative serum pregnancy test within 7 days before enrollment, and agree to use reliable effective throughout the study and for 3 months after the last study-drug dose. Male subjects with partners of child-bearing potential must agree to use reliable effective contraception throughout the study and for 3 months after the last study-drug dose. Lactating women are excluded.
  • The subject must be informed of the study prior to trial participation, voluntarily provide written , and be willing and able to comply with scheduled visits, treatment regimens, laboratory tests and other study-required procedures.

Exclusion criteria

Exclusion Criteria:

  • Diffuse hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, etc., confirmed by imaging or cytology.
  • Any prior history of immunotherapy with any of the following: grade 3 or higher immune-related adverse events (irAEs); toxicities that led to permanent discontinuation of prior /PD-L1 immunotherapy; disease progression assessed to occur within ≤ 3 months during previous immunotherapy.
  • Received treatment from another clinical trial within 4 weeks prior to the first study-drug administration, unless it is an observational (non-interventional) clinical trial or the subject is in the follow-up phase of an interventional trial; or received locoregional or systemic anti-cancer therapy within 28 days before the first study-drug administration.
  • History of bone marrow transplantation or solid-organ transplantation, or active chronic .
  • Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage. Subjects with asymptomatic mild pleural effusion, ascites or pericardial effusion identified by imaging are eligible.
  • Presence of hepatic encephalopathy or central nervous system .
  • For subjects positive for surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb): HBV-DNA must be \< 1 × 10⁴ copies/mL or 2000 IU/mL. Subjects with active hepatitis B must have received antiviral therapy for at least 14 days prior to enrollment (local standard-of-care agents such as entecavir or tenofovir are permitted), and agree to continue effective antiviral therapy during the study. HBV-DNA levels shall be monitored throughout treatment; antiviral therapy must be initiated once HBV-DNA turns positive and shall be maintained during the study and for 6 months after the last study-drug dose. Subjects positive for antibody must undergo HCV-RNA testing; subjects with HCV-RNA > 1 × 10³ copies/mL are excluded.
  • History of esophageal or gastric variceal bleeding secondary to portal hypertension within the preceding 6 months; subjects judged by the investigator to be at high bleeding risk. Any life-threatening bleeding event within the preceding 3 months, including bleeding requiring transfusion, surgery, locoregional intervention, or ongoing medical management.
  • History of arterial or venous thromboembolic events within the preceding 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or , pulmonary embolism, deep-vein thrombosis, or any other serious thromboembolic event. Thrombosis related to implantable venous access ports or catheters, or superficial venous thrombosis stabilized under routine anticoagulation are excluded from this criterion. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg daily) is allowed.
  • Continuous use of aspirin (> 325 mg/day) or other known -function inhibitors such as clopidogrel or ticlopidine within 2 weeks prior to first study-drug dose; known severe bleeding diathesis or coagulopathy; or ongoing thrombolytic therapy.
  • Abdominal wall fistula or gastrointestinal perforation, non-healed gastric ulcer, active gastrointestinal bleeding, or definite predisposition to gastrointestinal bleeding (e.g., known locally active ulcer lesions, faecal occult blood ≥ 2+) without targeted therapeutic intervention within 6 months before enrollment.
  • Uncontrolled comorbidities, including but not limited to: persistent or active infection; symptomatic congestive heart failure ( class II-IV with left-ventricular (LVEF) \< 50% on echocardiogram); uncontrolled diabetes; uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite optimal medical therapy, history of hypertensive crisis or hypertensive encephalopathy); cardiovascular disease; symptomatic or poorly controlled arrhythmias (congenital long- syndrome or corrected QTc > 500 ms calculated by Fridericia formula at screening); active interstitial lung disease or other pulmonary disorders with severe impairment of pulmonary function; history of nephropathy or nephrotic syndrome; severe chronic gastrointestinal disease accompanied by diarrhoea; or psychiatric/social conditions that may impair adherence to study procedures, substantially increase adverse-event risk, or compromise the subject's ability to provide written .
  • History of active primary immunodeficiency; (HIV) infection; active syphilis infection.
  • Active or clinically uncontrolled severe infection. Severe infection occurring within 4 weeks before first study-drug administration, including but not limited to hospitalization for infectious complications, sepsis, severe pneumonia, and active tuberculosis (currently receiving anti-tuberculosis therapy or having received anti-tuberculosis therapy within 1 year before first dosing).
  • Active disease requiring systemic therapy (e.g., disease-modifying agents, , ) within 2 years prior to first study-drug administration. Replacement therapies (e.g., thyroxine, insulin, physiological-dose corticosteroids for adrenal or pituitary insufficiency) are permitted. For subjects with positive autoantibodies only, the investigator must confirm the absence of clinical autoimmune disease. Use of immunosuppressive agents within 4 weeks before first dosing is excluded, except for intranasal, inhaled or other topical corticosteroids, or physiologic-dose systemic corticosteroids (i.e., ≤ 10 mg prednisone per day or equivalent).
  • Received within 4 weeks prior to first study-drug administration, or planned to receive live-attenuated vaccine during the study.
  • Major surgery (craniotomy, thoracotomy, laparotomy) performed within 4 weeks before first study-drug administration, or unhealed wounds, ulcers or fractures; tissue or venepuncture for intravenous infusion are exempted.
  • Diagnosis of other malignant neoplasms within 5 years prior to first study-drug administration, except for basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or radically resected carcinoma in-situ.
  • Known to any study drug or any of its .
  • Pregnant or lactating women.
  • Any other condition rendering the subject unsuitable for participation in this study, as judged by the investigator.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    Experimental

    TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

    Drug: QL1706 (Iparomlimab/Tuvonralimab)

Interventions

  • DrugQL1706 (Iparomlimab/Tuvonralimab)

    Drug page: Iparomlimab/Tuvonralimab

    TAE-HAIC Combined with Iparomlimab and Tuvonralimab (QL1706) and Lenvatinib

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Percentage of participants achieving objective response (CR or PR) maintained for at least 4 weeks assessed per mRECIST

    Time frame: From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

Secondary outcomes

  1. Duration of Response

    Time from first documented objective response to disease progression or death

    Time frame: From first study treatment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

  2. Disease Control Rate

    Percentage of participants achieving disease control (CR or PR or SD) maintained for at least 4 weeks assessed per mRECIST

    Time frame: From first study treatment up to maximum 3 years of participant treatment, until disease progression, withdrawal of consent, initiation of new anti-cancer therapy or intolerable toxicity, whichever occurs first

  3. Progression-Free Survival

    Time from enrollment to first-documented disease progression per mRECIST or death from any cause, whichever occurs first

    Time frame: From enrollment until disease progression or death from any cause (maximum participant follow-up 3 years after end of treatment)

  4. Overall Survival

    Time from enrollment to death from any cause

    Time frame: From enrollment until death from any cause (maximum participant follow-up 3 years after end of treatment)

  5. Incidence and severity of adverse events

    Treatment-emergent adverse events graded by CTCAE v5.0, including immune-related adverse events

    Time frame: From first study treatment through 30 days after last study-drug dose; immune-related adverse events followed through 90 days after last study-drug dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant-level data (IPD) will not be shared. This is a single-site, investigator-initiated exploratory phase II study. Access to individual-level participant data is restricted per institutional data governance requirements and local patient-privacy regulations. Data sharing outside of the approved study scope is not pre-planned for this trial.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2030, 38 months later.

Of 348 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 38 months is below that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 16, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Mar 1, 2030
CompletionEst.
Sep 1, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940478
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Mar 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Zhuting Fang, MD
Contact
470389481@qq.com
+8613805012709

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion